Although we have shown that MSN-MOG could suppress the development of EAE in semi-therapeutic study (Fig. 1f, g), MS in human is initiated before clinical symptoms appear, leading to the high demand for therapeutics to treat MS after the clinical diagnosis. This evidence concerns the gene MOG and myeloid sarcoma.